Edgewise Therapeutics Up 47%, Announces Topline Phase 1 and 2 Data for Heart Disease Treatment
Edgewise Therapeutics Up 47%, Announces Topline Phase 1 and 2 Data for Heart Disease Treatment
$Edgewise Therapeutics (EWTX.US)$ is up 47% in midday trading after announcing top-line data of EDG-7500 from its Phase 1 trial; the drug is designed to improve heart function in cardiomyopathy patients.
$Edgewise Therapeutics (EWTX.US)$ 在午盤交易中，股票上漲了47％，宣佈EDG-7500的一期試驗的頂線數據；這種藥物旨在改善心肌病患者的心臟功能。
“Based on the strength of clinical and preclinical data to-date, we have initiated the 28-day part of CIRRUS-HCM in patients with obstructive and non-obstructive HCM,” said Marc Semigran, M.D., Chief Development Officer, Edgewise Therapeutics, in a press release. “Importantly, we plan to continue the evaluation of tolerability, pharmacokinetics and effects on LVOT-G, LVEF, biomarkers and measures of feel and function in these patients.”
「根據迄今爲止的臨床和臨床前數據的強大實力，我們已經在梗阻性和非梗阻性HCm患者中啓動了CIRRUS-HCm的爲期28天的部分，」 Edgewise Therapeutics的首席發展官Marc Semigran萬.D.在新聞發佈會上表示。「重要的是，我們計劃繼續評估這些患者的耐受性，藥代動力學以及對LVOt-G，LVEF，生物標誌物和感受和功能的影響。」
In a separate Phase 2 single-dose trial for patients with obstructive hypertrophic cardiomyopathy (HCM)--a common cause of heart disease in young people--the company also shared positive data and expects to report initial 28-day data in the first quarter of 2025.
在一項針對患有梗阻性肥厚型心肌病（HCM）的患者的單劑量二期試驗中，該公司還分享了積極的數據，並預計將在2025年第一季度報告初步的28天數據。這是年輕人心臟病的常見原因。
